416 SOT Flashcards
Depleting agents for indication therapy
ATGAM
RATG
Alemtuzumab
Non-depleting agent for induction therapy
Basiliximab
MOA of antithymocytes (RATG, ATGAM)
Action against T and B cells
-apoptosis (release cytokines=premedicate)
RATG (Thymoglobulin) dosing
1-1.5 mg/kg given over 4-6hrs (round to nearest 25mg due to vial size)
AE of RATG
- leukopenia (hold therapy when WBC <3000)
- thrombocytopenia
- fever, chills, malaise, tachycardia
MOA of Alemtuzumab
CD52 antagonist
Alemtuzumab dosing
30mg SQ x1 prep
AE Alemtuzumab
Fever, chills, arthralgia, hypotension
-SQ decreases hypotension
MOA of Basiliximab
IL-2 receptor antagonist- prevents activation of IL-2 receptors
Dosing of Basiliximab
20mg IV within 2hrs prior to surgery then 20mg IV 3-4days after
Corticosteroids for induction therapy
Methylprednisolone 3mg/kg (or 1GM)
Antimicrobial prophylaxis for liver transplant
Unasyn 3g q6h for 24hrs
Antimicrobial prophylaxis for liver/small bowel
Zosyn 4.5g q6h for 24hrs
Antimicrobial prophylaxis for kidney OR heart
Cefazolin 1-2g q8h for 24hrs
Antimicrobial prophylaxis for kidney/pancreas
Cefoxitin 1-2g q8h for 24hrs
VTE prophylaxis
Heparin 5000 units SQ q8h OR
Lovenox 40mg SQ QD
Cyclosporine brand names for maintenance therapy
Sandimmune
Neoral
DO NOT switch
MOA of cyclosporine
Calcineurin inhibitor that inhibits secretion of IL-2
-inhibits T cell activation and proliferation
Tacrolimus brand names for maintenance therapy
Prograf
FK
MOA of Tacrolimus
Calcineurin inhibitor that inhibits secretion of IL-2
AE of calcineurin inhibitors (cyclosporine, tacrolimus)
nephrotoxicity
T>C: hyperglycemia, alopecia
C>T: HTN, HLD, hirsutism (TRT w/ Amlodipine, statin)
mycardial hypertrophy, electrolyte imbalance
DDI increase calcineurin levels
Azoles Diltiazem, verapamil Macrolides Amiodarone Warfarin Grapefruit juice
DDI decrease calcineurin levels
Phenytoin Phenobarbital Carbamazepine Rifampin St. John’s Wart
MOA of Sirolimus and Everolimus for maintenance therapy
mTOR inhibitor that inhibits response of IL-2
-inhibits T cell proliferation
Sirolimus dosing
6mg loading dose
2mg QD maintenance
AE of Sirolimus and Everolimus
myelosuppression
-leukopenia, thrombocytopenia
HLD
CI with Sirolimus
Voriconazole
Ketoconazole
Corticosteroid for maintenance therapy
Methylprednisolone 0.5-2mg/kg q6h tapered over next few days then transition to Prednisone 5-20mg QD
AE of corticosteroids
Hyperglycemia, HTN, altered mood, osteoporosis, glucose intolerance, HLD
Mycophenolate (MMF) brand names for maintenance therapy
Mycophenolate mofetil: Cellcept
Mycophenolate sodium: Myfortic
MOA of mycophenolate
Inhibitor of IMPDH (inhibits purine synthesis)
DDI with MMF
Acyclovir
Probenecid
Bile acid resins
Al or Mg antacids (Maalox)
AE of MMF
myelosuppression
PML
N/V/D
Teratogenic
MOA of Azathioprine for maintenance therapy
Inhibits cell division
Prohibits lymphoid cell production
BBW on Azathioprine
Increased risk of neoplasia has mutagenic potential and hematologic toxicity
DDI with Azathioprine
Allopurinol
AE of Azathioprine
myelosuppression
Alopecia, photosensitivity
MOA of Belatacept for maintenance therapy
Inhibits CD80-CD86 receptor
AE of Belatacept
N/V, anemia, peripheral edema
CMV prophylaxis
Especially +/-
Valganciclovir 450mg QD
PJP prophylaxis
Bactrim low dose
BID on two days per week
BK virus treatment
Cidofovir
Fungal infection treatment
Fluconazole
Voriconazole w/ heart/lung (cover aspergillus)
Cause HTN
Calcineurin inhibitors
Corticosteroids
Impaired kidney graft function
Treat HTN
Amlodipine (CCB)
Cause HLD
Calcineurin inhibitors
Corticosteroids
Sirolimus
Treat HLD
Rosuvastatin (statin)
Increased risk of DM
- AA or Hispanic
- age >40
- DM pretransplant
- family hx
- obesity
Increase risk of malignancies
> 5yrs post transplant
-skin cancers
PTLD (trt w/Rituximab)